The effectiveness of radiation therapy for human brain tumors is limited by the presence of radiation-resistant hypoxic cells. In order to improve patient outcomes, therapeutic methods that increase hypoxic cell killing must be developed. To investigate the possibility of using the hypoxic tumor microenvironment itself as a target for gene therapy, we stably transfected U-251 MG human glioblastoma cells with constructs containing the suicide gene Bax under the regulation of a nine-copy concatemer of hypoxia responsive elements (HREs). Previously, we demonstrated that the expression of BAX protein under anoxic conditions in transfected U-251 MG clones leads to increased cell killing in vitro. Our recent studies revealed that HIF-1a induction under anoxic conditions occurs prior to the increase in BAX expression, thereby implicating HIF-1 induction as the basis of BAX upregulation. To test the effect of BAX-mediated cell killing in vivo, we implanted five stably transfected clones subcutaneously into the flanks of athymic mice. Compared to nontransfected controls, tumor growth in four of five clones was significantly retarded. Histopathological analysis demonstrated decreased hypoxic fractions and increased amounts of apoptosis in clone-derived tumors. These results suggest that the tumor microenvironment is sufficiently hypoxic to trigger HRE-mediated cell killing via the BAX apoptotic pathway.
T he prognostic outlook for patients with glioblastoma is exceedingly grim-without therapy, patients uniformly die within 3 months. 1 Currently, the best treatment for glioblastoma consists of a combination of surgery, radiation therapy, and chemotherapy. Yet, even this aggressive, multimodal approach extends median survival by only a matter of months. 2, 3 A variety of factors combine to make glioblastoma such a notorious clinical challenge; among these is the presence of intratumoral regions of hypoxia. 4 The vast majority of human solid cancers, including glioblastoma, have lower median pO 2 levels than their normal tissue of origin. 5, 6 The presence of this hypoxic subpopulation of cancer cells is clinically significant for several reasons. In terms of radiation therapy, it is believed that the DNA radicals generated by radiation must react with oxygen in order to form the organic peroxides that ''fix'' the radiation damage and prevent it from being repaired. 7 Since the efficacy of radiation therapy hinges on the ability of surrounding normal tissue to tolerate doses of radiation that are cytotoxic to cancer cells, the presence of hypoxic cancer cells severely limits the utility of radiation treatment. 8 Other studies have demonstrated that hypoxic cancer cells are more resistant to chemotherapy than their oxic counterparts. 9, 10 The simplest explanation for this phenomenon is distance-cells furthest from blood vessels tend to be exposed to lower drug concentrations. Another hypothesis is that hypoxia itself can select for resistance. Studies show that hypoxia can cause cancer cells to enter a state of reduced proliferation, thus rendering them immune to the effects of most traditional modes of chemotherapy. 11 At the molecular level, the principal mediator of cellular responses to hypoxia is the protein hypoxiainducible factor-1 (HIF-1)-a transcriptional activator composed of two subunits, HIF-1a and HIF-1b. 12 Of the two subunits, HIF-1a is the unique O 2 -responsive polypeptide that regulates HIF-1 activity. Under hypoxic conditions, HIF-1 binds to an enhancer sequence known as the hypoxia-responsive element (HRE) and facilitates the transcription of downstream genes. 13 Genes regulated by HIF-1 include glycolytic and gluconeogenic enzymes, vascular endothelial growth factor (VEGF), tyrosine hydroxylase, and erythropoietin (Epo). 14 Previously, we have shown that HIF-1a is induced by anoxia in U-251 MG glioblastoma cells. 15 To investigate the possibility of using HIF-1 upregulation to drive the expression of a therapeutic gene, we generated five stably transfected clones of U-251 MG consisting of a nine-copy concatemer of HREs inserted adjacent to an SV40 minimal promoter in a mammalian expression vector containing the mouse variant of the proapoptotic Bax gene. 16, 17 The decision to construct clones with nine tandem repeats of HREs was based on earlier experiments that demonstrated that nine-copy HRE constructs led to greater induction of gene expression under anoxia than two-copy, three-copy, or six-copy constructs. 18 Of the five clones generated, one was selected for further in vitro characterization, and two were selected for in vivo immunohistological study. We subsequently conducted a series of experiments to assess the functionality of the HRE-Bax construct.
Materials and methods

Cell culture
U-251 MG human glioblastoma cells were obtained from the Department of Neurological Surgery Tissue Bank at the University of California, San Francisco (UCSF) and were maintained in complete growth medium (CMEM), which consists of Eagle's minimum essential medium supplemented with 1% nonessential amino acids and 10% fetal bovine serum. The process of stably transfecting and selecting HRE-Bax clones was performed as previously described. 18 Cells were maintained in CMEM containing 500 mg/ml G418 sulfate (Mediatech, Inc., Herndon, VA). All cells were cultured at 371C in a humidified atmosphere containing 95% air and 5% CO 2 .
Construction of nine-copy HRE-Bax
Construction of nine-copy HRE-Bax has been described previously. 15 Briefly, based on the published HRE sequence from the 3 0 enhancer region of the Epo gene, we designed pairs of oligonucleotides that contain three tandem repeats of the HRE. Nine-copy HRE was generated by tandem ligation of the three-copy HRE oligonucleotide pairs. These oligonucleotides were inserted into the multiple cloning sites of the mammalian expression vector/pbgal-promoter, which contains an enhancer-less SV40 promoter situated upstream of the LacZ gene. To construct nine-copy HRE-Bax, the LacZ gene in nine-copy HRE-LacZ was deleted using Hind III and Nde 1 restriction enzymes and replaced with a murine proapoptotic Bax cDNA fragment flanked by Hind III and Nde 1 sites.
Induction of anoxia in cultured tumor cells
Cells (3 Â 10 5 ) were seeded into 60 mm glass Petri dishes that were precoated with a 2% gelatin solution (Sigma Chemical Co., St Louis, MO). The following day, dishes were placed into gas-tight aluminum gassing jigs on a shaking platform at room temperature and flushed either with 95% air/5% CO 2 (oxic condition), 5% CO 2 
Animals
Female athymic mice (nu/nu genotype, BALB/c background), 5 weeks old, were purchased from Simonsen Laboratories (Gilroy, CA) and were housed under aseptic conditions and cared for in accordance with the United States Department of Health and Human Services Guide for the Care and Use of Laboratory Animals. All protocols were approved by the UCSF Institutional Animal Care and Use Committee.
Subcutaneous U-251 MG human glioblastoma xenografts
Implantation of tumor cells into the right flanks of athymic mice was performed as previously described. 18 Briefly, mice were anesthetized with inhalation of 2% isoflurane, and 5 Â 10 6 cells in 0.1 ml CMEM were injected subcutaneously into the right flanks. Tumor size was measured periodically using calipers, and tumor volume (V) was calculated as
, where L is the greatest length and W is the width of a perpendicular axis. Two separate implantation experiments were performed. In the first experiment, five mice were used for each clone group (Clones A, B, C, D, and E). Animals were euthanized on day 57 postimplantation, at which time Bax expression and tumor hypoxia were analyzed. We compared tumor size at day 53 among the six groups using the Dunnett many-to-one comparison procedure to allow for multiple comparisons to the control. If the P-value was less than 0.05 two-tailed, results were considered statistically significant. A total of 12 mice per group were used in the second experiment, which used tumors derived from Clones B and D and parent U-251 MG cells. Animals were euthanized when tumor volume reached predetermined end points (100, 300, 700, or 1000 mm 3 ), and the tumor tissue was subjected to immunohistopathological analysis. Owing to skin ulceration in some animals during the second trial, only 10 mice implanted with parental U-251 MG cells, 11 mice implanted with Clone D cells, and eight mice implanted with Clone B cells were used for analysis.
Western protein immunoblotting
Total protein was extracted from cultured cells or tumor tissue on ice with lysis buffer containing PBS, 0.5% deoxycholate, 1% Nonidet P-40, and 0.1% sodium dodecylsulfate in the presence of proteolytic inhibitors (2 mM phenylmethylsulfonyl fluoride, 10 mg/ml leupeptin, and 10 mg/ml aprotinin). The lysate was centrifuged at 14,000 rpm at 41C for 20 minutes and the soluble fraction was collected. Protein concentrations were measured using a Bio-Rad Protein Assay (Bio-Rad Laboratories, Inc., Hercules, CA). Equal amounts of total protein (25 mg) from each sample were separated electrophoretically in a 4-15% Tris-HCl SDS-PAGE gel (Bio-Rad), and transferred to a polyvinylidene difluoride membrane (Hybond-P; Amersham Life Sciences Corp., Piscataway, NJ). The membrane was stained for total protein using Ponceau-S (Sigma-Aldrich Corp., St Louis, MO) to ensure equal loading. Detection of protein on the immunoblots was performed using anti-human HIF-1a antibody raised in mouse (1:250 dilution; BD Biosciences Clontech, Palo Alto, CA), followed by peroxidaseconjugated horse anti-mouse IgG (1:30,000 dilution; Vector Laboratories, Burlingame, CA), as well as antimurine BAX monoclonal antibody and anti-human BAX monoclonal antibody (1:5000 dilution; R&D System, Inc., Minneapolis, MN) followed by goat anti-mouse IgG (1:50,000 dilution; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). The level of the signal obtained with anti-mouse BAX and anti-human BAX antibodies does not necessary reflect a difference between levels of human and mouse proteins, as these signals were generated by different antibodies. Immunoreactive bands were detected using the SuperSignal chemiluminescent detection system (Pierce, Rockford, IL) and visualized by autoradiography (Amersham Biosciences, Buckinghamshire, England). Densitometry was used for image analysis (ImageQuant, Molecular Dynamics, Sunnyvale, CA).
Immunohistochemistry and histopathology
Pimonidazole hydrochroride (Hypoxyprobe TM -1; Natural Pharmacia International, Inc., Research Triangle Park, NC) was dissolved in normal saline to a concentration of 20 mg/ml. Animals were injected intraperitoneally with 60 mg/kg of pimonidazole 1.5 hours before euthanasia. Anesthetized mice were then perfused with 10% buffered formalin and flank tumors were dissected from the animals. Tumors were kept in 10% buffered formalin overnight and then embedded in paraffin. Sections (8 mm) were deparaffinized, incubated at room temperature for 40 minutes with a 1:50 dilution of mouse anti-hypoxyprobe-1 antibody (Natural Pharmacia International, Inc.), and then incubated for 10 minutes with a biotinsp-conjugated anti-mouse F(ab')2 antibody. Antigens were visualized with horseradish peroxidase and diaminobenzindine (DAKO, Carpinteria, CA), and hematoxylin was used as a final counterstain. The ApoTag Kit (Serological Corp., Norcross, GA) was used to stain apoptotic cells using the procedure described by Shinohara et al. 19 Paraffin-embedded tumors were also sectioned to a 5 mm thickness and stained with hematoxylin and eosin using standard staining methodology. The degree of necrosis in the tumor was assessed subjectively.
Results
Hypoxia induces mouse-BAX expression in stably transfected U-251 MG clone cells
Using Western blot analysis, we compared mouse-BAX (mBAX) expression levels under oxic and anoxic conditions (Fig 1) . All five clones exhibited increased mBAX expression under anoxic as compared to oxic conditions; however, of the five clones generated, Clone D cells were selected for further in vitro analysis because they demonstrated the greatest ratio of anoxic to oxic mBAX expression and almost no expression under oxic conditions. As shown in Figure 2a , HIF-1a was induced specifically in response to anoxia, following exposure of both parent and Clone D cell lines to an anoxic period from 4 to 24 hours. Mouse-BAX was expressed specifically by Clone D cells subjected to either 16 or 24 hours of anoxia, which suggested that the demonstrated level of HIF-1a induction was sufficient to drive HRE-mediated BAX expression. The observation that HIF-1a induction preceded mBAX expression is consistent with the notion that mBax transcription occurs in response to HIF-1 binding to the nine-copy HRE construct. We subsequently reprobed the same immunoblot membrane with anti-human BAX antibody to rule out changes in Figure 1 Western blot analysis of mouse-BAX (mBAX) expression in five U-251 MG clones (labeled A-E) that were stably transfected with the HRE-Bax construct. The N 2 :O 2 ratio refers to the ratio of mBAX expression as measured by densitometry after 16 hours of anoxic versus oxic conditions.
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expression of the human-BAX (hBAX) as one possible cause for the observed effect. As shown in Figure 2a , no consistent relationship between oxic versus anoxic hBAX expression in either parent or Clone D cells was demonstrable.
As physiologic intratumoral oxygen saturation spans the range between normoxia and anoxia, we also compared mBAX expression levels under conditions of 0.3 and 1% oxygen-levels consistent with those found in the hypoxic subpopulation of cells within human brain tumors. 20, 21 As was true under anoxic conditions, hBAX expression under these intermediate oxygen concentrations was not induced in either parental or Clone D cells. However, HIF-1a expression was induced by hypoxia in both types of cells, whereas mBAX expression was seen only in Clone D cells that were exposed to hypoxia (Fig  2b) . Although it is not possible to quantitatively compare results shown in Figure 2a and b, owing to experimental differences in photographic exposure, the results shown in Figure 2b reiterate the idea that HIF-1 upregulation is capable of driving mBAX expression, and demonstrate the feasibility of this approach even under conditions of intermediate oxygenation.
Clone D cells exhibit an increased level of apoptosis under anoxic conditions
To determine whether the induction of mBAX leads to a demonstrable increase in apoptosis, we conducted fluorescence microscopy with live Clone D cells and parent U-251 MG cells exposed to anoxic conditions for 4, 16, or 24 hours (Fig 3) . The percentage of apoptotic Clone D cells under oxic conditions was 1.2%, and this increased to B45-65% under anoxic conditions. The percentage of apoptotic parent U-251 MG cells was B3% under oxic or anoxic conditions at all time points tested (data not shown). These data strongly suggest that the HRE-Bax construct was being activated by anoxia to induce apoptosis.
Clone-derived tumors exhibit slower growth
To assess whether in vivo tumor conditions are sufficiently hypoxic to trigger apoptosis via the HRE-Bax pathway, one tumor from each set of clone-derived tumors was analyzed for BAX expression. As shown in Figure 4 , mBAX expression, while absent in nontransfected parent U-251 MG cells, was uniformly positive in the clonederived tumors, thus confirming the in vivo functionality of the HRE-Bax construct. Human-BAX was expressed in all tumors, including those derived from parent cells. As shown in Figure 5 , growth curves indicate slower growth, as well as less consistency in growth, for all clones compared to historical parent U-251 MG data. Four animals in the control group were euthanized due to tumor burden prior to day 53. Their last tumor size was used in the analysis. All but Clone B met the criterion for declaring statistical significance using the Dunnett manyto-one comparison procedure. While these tests are not Hypoxia-induced BAX expression in glioblastoma T Ozawa et al definitive because of the relatively small number of animals, they do confirm the information seen visually in the figures.
Clone-derived tumors have a smaller hypoxic fraction and exhibit increased apoptosis
To assess in vivo tumor hypoxia, a minimum of two tumors from each set of clone-derived tumors were stained with pimonidazole, a nitroimidazole derivative that is selectively bound and reduced in hypoxic cells. 22, 23 All sections of clone-derived tumors exhibited none or few positive pimonidazole-stained cells (data not shown). Two clones-Clone B and Clone D-were selected for further immunohistological analysis. Clone D was chosen because it demonstrated the greatest ratio of anoxic to oxic mBAX expression among the clones, and Clone B was chosen because it exhibited the smallest ratio of anoxic to oxic mBAX expression among the clones (Fig 1) . Upon visual assessment of these two clones following tumor removal on postimplantation day 57, Clone B tumors exhibited a degree of necrosis ranging from 60 to 70%, while Clone D tumors exhibited less necrosis (5-40%) (data not shown).
To assess whether the difference in necrosis between Clone B and Clone D relates to real differences in the relative functionality of the HRE-Bax construct between these two clones, as opposed to simply reflecting differences in tumor size at the time of euthanasia, we conducted another set of experiments at equal tumor volumes. 
Discussion
Until recently, the clinical ramifications of an elevated hypoxic tumor fraction were universally negative. Our results, however, indicate that it may be feasible to use intratumoral hypoxia for therapeutic advantage. Using human glioblastoma clones that have been stably transfected with an HRE-Bax construct, we show that it is possible to specifically target and kill hypoxic cells.
The appeal of this strategy is manifold. Targeting hypoxic cells for apoptosis not only selects neoplastic cells preferentially over normal cells but also selects the very cells that are most refractive to traditional modes of therapy. 24 Hypoxia-targeted gene therapy is therefore theoretically an excellent complement to radiation therapy. Indeed, when interpreting the data shown here, one should bear in mind that combination therapy is the ultimate goal. Thus, the growth retardation exhibited by clone-derived flank tumors in Figure 5 , while modest in absolute terms, is fairly remarkable when one considers that the cells not killed by hypoxia-driven apoptosis should be oxic and therefore quite susceptible to radiation. As shown in Figure 6 , clone-derived tumors are much more oxic than their nontransfected counterparts.
Of course, growth was not uniformly inhibited in clonederived tumors, which suggests that there is a complex interplay between environmental and genetic factors that influences tumor growth in a manner not yet completely understood. The slower growth of Clone D versus Clone B tumors, for instance, may reflect a more robust apoptotic response to hypoxia in Clone D tumors. Alternatively, Clone B tumors may, for whatever reason, simply grow faster than Clone D tumors, or have a relatively increased oxic fraction that is not susceptible to hypoxia-targeted gene therapy.
Hypoxia-mediated BAX expression may also help repair the imbalance between growth and apoptosis that underlies all neoplastic progression. On a molecular level, the balance between growth and apoptosis is reflected in the delicate equilibrium between proapoptotic mediators (such as BAX) and antiapoptotic mediators (such as Bcl-2). 25 Another important player is the tumor suppressor protein p53, which plays a key role in triggering apoptosis. 26 The glioblastoma cell line used in our experiments, like so many other cancer cell lines, contains a p53 gene mutation. 27 As a consequence, these cells are likely to have a relative deficit of proapoptotic mediators. Perhaps, therefore, the additional BAX expression afforded by the HRE-Bax construct is enough to shift the balance between pro-and antiapoptotic mediators in favor of apoptosis.
Our next goal is to develop a vector capable of delivering the HRE-Bax construct to athymic rats with intracerebral tumors. Using an adeno-associated viral (AAV) vector containing a LacZ reporter gene under the transcriptional control of HRE, we have previously shown that gene expression is strongly upregulated under anoxic conditions in infected glioblastoma cells. 18 We have also demonstrated that there is no significant difference between the infection efficiency of AAV-CMV-LacZ (without HRE) to U 251-MG cells under oxic and anoxic conditions, at pH 7.2 and pH 6.5, and at log and plateau phases of growth (unpublished data). Other investigators have already utilized the AAV model with success, although none have linked BAX expression to HRE. Li et al 28 have shown that adenovirus-mediated overexpression of BAX induces apoptosis in prostate cancer cells in vivo. Su et al 29 have demonstrated that in vivo injection of mouse myocardium with an AAV vector containing the VEGF gene under the control of HRE leads to hypoxia-specific VEGF expression.
In conclusion, the results shown here demonstrate that targeting hypoxic glioblastoma cells for apoptosis is a therapeutic approach with great promise. Since so many cancers contain significant regions of hypoxia, the HREBax system used here could potentially be effective in treating a wide range of cancers. Indeed, the discovery that hypoxia may be associated with metastatic spread suggests that hypoxia-targeted gene therapy may provide a means of preventing distant metastases. 30 Given the genetic heterogeneity of cancer cells, targeting a physiologic condition such as hypoxia may ultimately prove to be a more efficient method of gene therapy than targeting the gene products themselves. Hypoxia-induced BAX expression in glioblastoma T Ozawa et al
